Author:
Ferron Géraldine M.,Dai Yang,Semiond Dorothée
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference23 articles.
1. Mita AC, Denis LJ, Rowinsky EK, de Bono JS, Goetz AD, Ochoa L, Forouzesh B, Beeram M, Patnaik A, Molpus K, Semiond D, Besenval M, Tolcher AW (2009) Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 15:723–730
2. Bissery M-C, Bouchard H, Riou JF, Vrignaud P, Combeau J, Bourzat JD, Commercon A, Lavelle F (2000) Preclinical evaluation of TXD258, a new taxoid [abstract #1364]. Proc Am Assoc Cancer Res 41:214
3. Vrignaud P, Lejeune P, Chaplin D, Lavelle F, Bissery M-C (2000) In vivo efficacy of TXD258, a new taxoid, against human tumor xenografts [abstract #1365]. Proc Am Assoc Cancer Res 41:214
4. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154
5. Dieras V, Lortholary A, Laurence V, Delva R, Girre V, Livartowski A, Assadourian S, Semiond D, Pierga JY (2012) Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study. Eur J Cancer doi: 10.1016/j.ejca.2012.07.008 . [Epub ahead of print]
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献